Armanino Foods of Distinction ( AMNF ), Turning Point Brands ( TPB ), and Mama's Creations ( MAMA ) ranked among the market's least attractively valued small-cap U.S. consumer staples stocks based on their valuation grades. The valuation grade measures how expensive or inexpensive a stock is relative to others in its sector. It incorporates several metrics, including P/E, PEG, price-to-sales, and ...
Armanino Foods of Distinction ( AMNF ), Turning Point Brands ( TPB ), and Mama's Creations ( MAMA ) ranked among the market's least attractively valued small-cap U.S. consumer staples stocks based on their valuation grades. The valuation grade measures how expensive or inexpensive a stock is relative to others in its sector. It incorporates several metrics, including P/E, PEG, price-to-sales, and price-to-cash-flow ratios, using both current and forward-looking estimates. The overall grade is calculated from these underlying metrics and indicates how attractively a stock is valued compared with its sector peers. Most expensive U.S. stock by valuation grade (market cap between $300M and $2B): Armanino Foods of Distinction ( AMNF ) F Turning Point Brands ( TPB ) F Mama's Creations ( MAMA ) D- John B. Sanfilippo & Son ( JBSS ) D+ Lifeway Foods ( LWAY ) D+ Olaplex Holdings ( OLPX ) D+ The Honest Company ( HNST ) C- Natural Grocers by Vitamin Cottage ( NGVC ) C- The Boston Beer Company ( SAM ) C- BRC ( BRCC ) C More on Consumer Staples Natural Grocers By Vitamin Cottage Looks Tasty Natural Grocers by Vitamin Cottage, Inc. 2026 Q2 - Results - Earnings Call Presentation Lifeway Foods: The End Of The Danone Support Is Not A Drawback Black Rifle Coffee regains compliance with NYSE minimum share price requirement Black Rifle Coffee regains NYSE compliance after share price improvement
bra_nec/iStock via Getty Images Overview Credit funds continue to face headwinds as a result of higher interest rates, and this has made it challenging for income investors to find a safe haven. Barings Corporate Investors ( MCI ) offers investors a way to get exposure to a diversified portfolio of debt investments and has a solid track record. When I previously covered MCI, I issued a hold rating...
bra_nec/iStock via Getty Images Overview Credit funds continue to face headwinds as a result of higher interest rates, and this has made it challenging for income investors to find a safe haven. Barings Corporate Investors ( MCI ) offers investors a way to get exposure to a diversified portfolio of debt investments and has a solid track record. When I previously covered MCI, I issued a hold rating due to the premium valuation and inconsistent earnings at the time. Since then, the macroeconomic environment and outlook have shifted, so I wanted to reassess MCI's overall value proposition for the remainder of the year. When I previously covered MCI, the fund traded at a premium to NAV of 10.5%. Following the pullback in share price, the fund now trades at a slightly smaller premium to NAV of 6.58%. Now that the share price has pulled back from its highs, MCI's valuation is a bit more attractive. Referring to the red line on the graph below, we can see that MCI trades in the middle of its historical price-to-NAV range. For instance, the fund has traded at an average premium to NAV of about 10.71% over the last three years. CEF Data However, I believe that there are some risks that investors should take into consideration before initiating a position. For instance, it appears that interest rates are now more likely to be hiked than cut by the end of the year. A higher interest rate environment can create negative sentiment in the debt market and have a direct impact on MCI's share price. Furthermore, the fund now offers a high dividend yield of 9%, but the latest earnings data indicates that MCI is actively paying out more than it actually earns. If the portfolio's performance does not improve, a dividend cut may be needed. Fund Strategy According to the latest available quarterly update , MCI now has total assets of $424.2M that are spread across a diverse portfolio of debt securities. The fund's main objective is to provide a high current income, which it achieves by i...
Commercial vessel traffic through the crucial Strait of Hormuz appeared to remain limited over the past day, amid uncertainty over prospects for a US-Iran peace deal. Just two inbound commercial transits were observed on Tuesday morning, following two outbound ships on Monday, according to ship-tracking data compiled by Bloomberg. Shipowners had recently become more optimistic about a pickup in tr...
Commercial vessel traffic through the crucial Strait of Hormuz appeared to remain limited over the past day, amid uncertainty over prospects for a US-Iran peace deal. Just two inbound commercial transits were observed on Tuesday morning, following two outbound ships on Monday, according to ship-tracking data compiled by Bloomberg. Shipowners had recently become more optimistic about a pickup in traffic with guidance from the US, and Iran’s semi-official Tasnim news agency on Tuesday said 24 vessels transited the waterway over the past 24 hours after obtaining permission from the Islamic Revolutionary Guard Corps. The figure is difficult to confirm independently because electronic interference and tracking gaps suggest the total may bundle smaller coastal craft with large commercial ships. Read More: The Iran War Is Pushing the Global Gas Trade Into the Shadows President Donald Trump is still hopeful the US can reach an interim peace deal with Iran soon, after the Islamic Republic threatened to suspend talks because of Israel’s escalating attacks in Lebanon. Officials in Tehran are discussing their “final text” to send to the US, Iran’s Mehr news agency reported, citing a person close to the negotiating team. The report reiterated that the country’s negotiators were wary of the US, saying it had breached previous pledges. An Iranian fuel carrier and a Chinese oil products tanker entered the Persian Gulf on Tuesday, after an Iranian liquefied petroleum gas carrier and a Turkish bulker exited the waterway on Monday. Regional shipping patterns remain disrupted by the US blockade of Iranian vessels in the Gulf of Oman. On Monday , American military officials reported that a total of 121 commercial ships have been rerouted. Persistent AIS interference continues to obscure vessel movements, with transit counts likely to be revised as ships reappear beyond high-risk waters. The US naval presence may also be distorting the observations. Iran-linked vessels entering or leavin...
The company reported sales of 383,453 new energy vehicles (NEVs) in May, a marginal increase of 0.3% from 382,476 units sold in the same month a year earlier.
The company reported sales of 383,453 new energy vehicles (NEVs) in May, a marginal increase of 0.3% from 382,476 units sold in the same month a year earlier.
Hailshadow Legend Biotech ( LGND ) added ~26% in the morning hours on Tuesday after announcing initial results from an early-stage trial for LB2501, its in vivo CAR-T cell therapy targeting B-cell non-Hodgkin lymphoma, the most common form of non-Hodgkin lymphoma. Citing data from its ongoing Phase 1 trial for patients with B-NHL, the cell therapy developer said that LB2501 at the second dose leve...
Hailshadow Legend Biotech ( LGND ) added ~26% in the morning hours on Tuesday after announcing initial results from an early-stage trial for LB2501, its in vivo CAR-T cell therapy targeting B-cell non-Hodgkin lymphoma, the most common form of non-Hodgkin lymphoma. Citing data from its ongoing Phase 1 trial for patients with B-NHL, the cell therapy developer said that LB2501 at the second dose level led to a 100% objective response rate, including an approximately 84% complete response rate at a median follow-up of 2.2 months. In vivo CAR-T cell therapies designed to generate CAR-T cells inside the patient’s body are simpler to manufacture and administer than ex vivo therapies, which require cell manufacturing and lymphodepletion. The readout also indicated no dose-limiting toxicities, serious adverse events, or deaths, according to the company. However, nearly 70% of patients witnessed events categorized as cytokine release syndrome at a severity level of Grade 2 or below. The results obtained on April 1, 2026, from 12 patients with relapsed/refractory B-NHL have been selected for a presentation at the upcoming European Hematology Association 2026 Congress. More on Ligand Pharmaceuticals Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript Ligand Pharmaceuticals Incorporated 2026 Q1 - Results - Earnings Call Presentation Ligand Pharmaceuticals Incorporated (LGND) XOMA Royalty Corporation - M&A Call - Slideshow Ligand Pharmaceuticals Q1 2026 Earnings Preview Ligand to buy XOMA Royalty for $39/share
(RTTNews) - Stocks continue to show a lack of direction during trading on Tuesday but have maintained the positive bias seen over the two previous sessions. While buying interest seems somewhat subdued, the major averages have all moved to the upside on the day.
(RTTNews) - Stocks continue to show a lack of direction during trading on Tuesday but have maintained the positive bias seen over the two previous sessions. While buying interest seems somewhat subdued, the major averages have all moved to the upside on the day.